WALTHAM, Mass., May 23, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,256,269 shares of its common stock (or pre-funded warrants in…Read More
Checkpoint Therapeutics Announces 10 Million Registered Direct Offering Priced AttheMarket Under Nasdaq Rules
